

PRESS RELEASE – FOR IMMEDIATE RELEASE

**IntegraGen Announces Collaboration with the French Intergroup of Thoracic Oncology (IFCT) to Explore the Role of miR-31-3p Biomarker in Non-Small Cell Lung Cancer**

---

**EVRY, France, September 2, 2014** - IntegraGen, a French leader in genomics services also specializing in the development of molecular diagnostic tests for oncology and autism, today announced a collaboration with the French Intergroup of Thoracic Oncology (IFCT) to explore the role of its proprietary miR-31-3p biomarker in advanced stage non-small cell lung cancer (NSCLC). The study aims to identify whether the expression of the microRNA miR-31-3p is correlated with outcomes associated with the use of epidermal growth factor receptor (EGFR) targeted therapies for lepidic adenocarcinomas of the lung. If the results from this initial study are positive, the collaboration could be expanded to additional IFCT studies with miR-31-3p exploring its association with EGFR-targeted therapy-related outcomes in other types of lung cancer.

"This collaboration will allow us to explore the correlation between the expression of miR-31-3p in the tumor and the effects of EGFR inhibitors in patients with advanced NSCLC," said Francois Liebaert, M.D., IntegraGen's Vice-President of R&D and Medical Affairs. "We are particularly pleased to have the opportunity to collaborate with the IFCT, the leading French cooperative group in the field of lung cancer."

"This project with IntegraGen will build on translational research and other studies conducted by the IFCT designed to identify molecular markers for lung cancer," commented Prof. Jacques Cadranel, a Member of the IFCT Scientific Council and coordinating investigator for both the IFCT-0401 and IFCT-0504 clinical trials from which samples for the study of miR-31-3p will be obtained. "This study will enable us to explore a biomarker which is potentially capable of guiding treatment in patients with lung cancer identifying who will benefit most from therapies and potentially allowing us to avoid unnecessary and expensive chemotherapy options."

Lung cancer is the most common form of cancer worldwide with approximately 1.8 million cases diagnosed on an annual basis. Lung cancer is also the leading cause of cancer-related mortality being responsible for nearly one in five cancer-related deaths.

IntegraGen [presented data](#) at 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) reporting the predictive effects of miR-31-3p on outcomes associated with anti-EGFR therapy in patients with metastatic colorectal cancer. If the collaborative studies with the IFCT are conclusive, this would expand the use of miR-31-3p testing to other types of cancer. IntegraGen has the exclusive license for the worldwide rights for the miR-31-3p biomarker. The company, along with Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris, are co-owners of the patent.

**ABOUT INTEGRAGEN**

Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen's

mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

IntegraGen had total revenues annual of €5.4 million for 2013. Headquartered in Evry Genopole in France, IntegraGen had 32 employees as of December 31, 2013. The Company also has a U.S. subsidiary, IntegraGen Inc., based in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - Eligible PEA-SME)

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com).



## **ABOUT THE IFCT**

Created 15 years ago, the French Intergroup for Thoracic Oncology (IFCT) includes 450 physicians from various disciplines working in the field of lung cancer. The IFCT is an advocate of clinical studies and is supported by a national network of 250 centers (university hospitals, centers for the fight against cancer, general hospitals and private clinics). IFCT projects are coordinated by a Clinical Research Unit accredited by the National Cancer Institute (INCA) and the National League Against Cancer. Funded by various sources of public and industrial funds, the IFCT is strongly committed to conducting independent studies. The IFCT in figures: 600 investigators, 250 centers across France, nearly 9,000 patients included in 28 studies since 1999, and 9 current studies with active patient recruitment.

For more information on the IFCT visit [www.ifct.fr](http://www.ifct.fr)

## **CONTACTS**

### **INTEGRAGEN**

Bernard COURTIEU  
President and Chief Executive Officer

Laurence RIOT LAMOTTE  
Chief Financial Officer  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel. : +33 (0)1 60 91 09 00

### **NEWCAP.**

**Investor and Medical Relations**  
Emmanuel HUYNH  
Louis-Victor DELOUVRIER  
[integragen@newcap.fr](mailto:integragen@newcap.fr)  
Tel. : +33 (0)1 44 71 94 94